Tempus AI Reports Strong Q3 2026 Revenue Growth and Positive Adjusted EBITDA, Driven by Data Licensing and Regulatory Approvals
Trendline

Tempus AI Reports Strong Q3 2026 Revenue Growth and Positive Adjusted EBITDA, Driven by Data Licensing and Regulatory Approvals

What's Happening? Tempus AI, an AI-powered precision medicine and genomic testing company, announced significant financial results for its third quarter of 2026. The company reported total revenue of $411.5 million, marking a 23% increase year-over-year. Crucially, Tempus AI achieved a positive adju
AI Generated
This may include content generated using AI tools. Glance teams are making active and commercially reasonable efforts to moderate all AI generated content. Glance moderation processes are improving however our processes are carried out on a best-effort basis and may not be exhaustive in nature. Glance encourage our users to consume the content judiciously and rely on their own research for accuracy of facts. Glance maintains that all AI generated content here is for entertainment purposes only.